For all cancers in which they are negatively regulated, ING1 and ING2 protein levels decreased in the nucleus, suggesting a mutation closer to their NLS domain and/or an impaired interaction with a protein required to target ING1 and ING2 to the nucleus. The gene discussed is ING2; the disease is cancer.